IMMUNE / INFLAMMATION / PEPTIDE CARD

KPV

A tripeptide fragment derived from alpha-melanocyte-stimulating hormone and studied primarily in preclinical inflammation models.

PEPTIDE CARDKPV

Reviewed
August 8, 2026

Human evidence

1/5 · Preclinical evidence only

U.S. FDANot FDA approved

2026 WADANot specifically named

Inspect 3 sources

On this page

WHAT THE EVIDENCE SAYS

KPV evidence summary.

KPV has a plausible anti-inflammatory research story in cells and animals, but that evidence has not established a safe or effective human drug product.

Entity type
Peptide fragmentSource snapshot
August 8, 2026Record status
Sources attached

Do not overread this record

Results in human-derived cells are not clinical evidence in people, and they do not resolve product quality or dosing questions.

01 / CLASSIFICATION

What is KPV?

Entity typePeptide fragment

Research categoryImmune / Inflammation

Known namesKPV

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Innate-immunity and inflammation peptides Goal: Immune & Inflammation

02 / EVIDENCE

KPV human and preclinical evidence.

HUMAN

1/5 · Preclinical evidence only

Published work includes human intestinal cell models, but no completed clinical efficacy program was identified.

PRECLINICAL

3/5 · Inflammation models

Cell and mouse colitis studies support a research signal without establishing a human treatment effect.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

KPV FDA and sport status.

U.S. FDANo FDA-approved drug product; FDA reports no identified human exposure data for compounded KPV products and insufficient safety information.

2026 WADANot specifically named in the 2026 WADA List; athletes should verify current status and product contents.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is KPV being studied for?

01Intestinal inflammation

02Melanocortin signaling

03Peptide transport

04Innate immunity

05 / COMPARISONS

Compare KPV.

BPC-157 vs KPVTwo unapproved peptides discussed for inflammation and gastrointestinal research.KPV vs LL-37Two innate-immune research peptides with different mechanisms and similarly limited therapeutic evidence.

06 / LATEST & DEFINING SOURCES

KPV primary and official sources.

Preclinical / 2008PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

PubMed

FDA / 2026Bulk substances that may present significant safety risks

U.S. FDA

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about KPV.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for KPV?

KPV has a plausible anti-inflammatory research story in cells and animals, but that evidence has not established a safe or effective human drug product.

ResearchWhat is KPV being studied for?

Current source-backed research areas include Intestinal inflammation, Melanocortin signaling, Peptide transport, Innate immunity. These areas describe investigation, not established personal benefit.

FDA statusIs KPV FDA approved?

Current U.S. status for KPV: No FDA-approved drug product; FDA reports no identified human exposure data for compounded KPV products and insufficient safety information.

Sport statusIs KPV prohibited in sport?

Current sport-status snapshot for KPV: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.

Evidence limitsWhat are the main evidence limits for KPV?

Results in human-derived cells are not clinical evidence in people, and they do not resolve product quality or dosing questions.